Read more

July 19, 2024
3 min watch
Save

VIDEO: Phase 3 bel-sar trial focuses on choroidal melanoma

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Jill Hopkins, MD, of Aura Biosciences discusses a phase 3 program in ocular oncology.

The trial, which is currently enrolling, will investigate belzupacap sarotalocan (bel-sar) delivered through a suprachoroidal injection and activated with a laser in patients with choroidal melanoma. According to Hopkins, a phase 2 program demonstrated encouraging results in tumor regression and vision preservation.

“This potential for bel-sar to be effective in stopping tumor growth and preserving vision would show a significant paradigm shift for patients who currently have radiotherapy as their only available option,” she said.

Reference:

Enduring content from the Clinical Trials at the Summit 2024 meeting can be accessed here:
https://www.ctsretina.org/cts-2024-enduring.